Application No.: 10/588,685

Filed: June 21, 2007

Page 2

## Amendments to the Claims

Please amend claims 1, 3-17, and 31.

Please cancel claims 18-22.

The listing of claims will replace all prior versions, and listings of claims in the application.

## **Listing of Claims**

- 1. (Currently Amended) A method for producing <u>non-methylated</u> DNA, wherein a <u>for use in</u> methylation analysis is used, comprising the steps of:
- a) performing a genome-wide amplification on genomic DNA[[,]] <u>using non-methylated nucleotides or nucleotide triphosphates</u>, thereby producing fully non-methylated DNA; and
- b) using the amplificates generated in step a) as a non-methylated standard in the methylation analysis over a linear range.
- 2. (Canceled).
- 3. (Currently Amended) A <u>The</u> method of claim 1, wherein the amplification methods performed are is PEP, DOP-PCR or linker PCR.
- 4. (Currently Amended) A <u>The</u> method of claim 1, wherein the amplification method performed is a multiple displacement amplification (MDA).
- 5. (Currently Amended) A <u>The</u> method of claim 4, further comprising using a φ29-Polymerase.
- 6. (Currently Amended) A <u>The</u> method of claim 4, further comprising using a commercially available kit.
- 7. (Currently Amended) A <u>The</u> method of claim 6, wherein the commercially available kits are "GenomiPhi" (Amersham Biosciences) or "Repli-g" (Molecular Staging).

PATENT Attorney Docket No. EPIGEN1280

In the Application of:
Fabian Model, *et al*.
Application No.: 10/588,685

Filed: June 21, 2007

Page 3

- 8. (Currently Amended) A <u>The</u> method of claim 4, further comprising a commercial<u>ly</u> available DNA produced by MDA is used as a standard.
- 9. (Currently Amended) A <u>The</u> method of claim 1, further comprising using restriction enzymes.
- 10. (Currently Amended) A <u>The</u> method of claim 1, further comprising performing the methylation analysis after conversion of the DNA into a form, in which methylated cytosines can be distinguished from non-methylated cytosines by means of hybridization, by methylation-specific ligation methods, MSP, Heavy Methyl or MethyLight.
- 11. (Currently Amended) A <u>The</u> method of claim 1, further comprising performing the methylation analysis after conversion of the DNA into a form, in which methylated cytosines can be distinguished from non-methylated cytosines by means of hybridization, by primer extension.
- 12. (Currently Amended) A <u>The</u> method of claim 1, further comprising performing the methylation analysis after conversion of the DNA into a form, in which methylated cytosines can be distinguished from non-methylated cytosines by means of hybridization, by an amplification and a hybridization of the amplificates at oligomer microarrays.
- 13. (Currently Amended) A <u>The</u> method of claim 1, further comprising performing the methylation analysis after conversion of the DNA into a form, in which methylated cytosines can be distinguished from non-methylated cytosines by means of hybridization, by means of a multiplex PCR.
- 14. (Currently Amended) A <u>The</u> method of claim 1, wherein a <u>mixture of methylated and methylated DNA is mixed with the</u> non-methylated DNA <u>in a known amount to produce a mixture that is used as a standard.</u>
- 15. (Currently Amended) A <u>The</u> methods of claim 1, wherein several mixtures of methylated and methylated DNA is mixed with the non-methylated DNA in known amounts to produce mixtures with different shares of methylated and non-methylated DNA that are used as a standards.

PATENT Attorney Docket No. EPIGEN1280

In the Application of:
Fabian Model, *et al*.
Application No.: 10/588,685

Filed: June 21, 2007

Page 4

16. (Currently Amended) A <u>The</u> method of claim 1, wherein the methylation analysis is performed for the diagnosis of cancer diseases or other diseases associated with a modification of the methylation status.

17. (Currently Amended) A <u>The</u> method of claim 1, wherein the methylation analysis is performed for the prognosis of desired or undesired effects of drugs and for the differentiation of cell types or tissues, or for the investigation of the cell differentiation.

18-30. (Canceled).

31. (Currently Amended) A <u>The</u> method of claim 1, wherein the <del>genome wide amplification</del> is performed by exclusively using <u>non-methylated</u> nucleotides or nucleotide triphosphates, respectively, which are non-methylated are cytosine.

32-39. (Canceled).